Detalhe da pesquisa
1.
A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors.
Cancers (Basel)
; 16(6)2024 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38539472
2.
Exon-Intron Differential Analysis Reveals the Role of Competing Endogenous RNAs in Post-Transcriptional Regulation of Translation.
Noncoding RNA
; 7(2)2021 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-33923420
3.
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).
Eur J Cancer
; 96: 6-16, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29660598
4.
5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.
J Med Chem
; 60(17): 7524-7538, 2017 09 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-28829592
5.
Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention.
Nat Commun
; 8: 14683, 2017 03 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28276440